FOLFIRI双周方案治疗晚期结直肠癌不良反应60例临床观察  

Clinical observation of adverse reactions of 60 metastatic colon-rectal cancer cases treated with double-week FOLFIRI

作　　者：林鑫[1] 崔同建[1] 

机构地区：[1]福建省立医院肿瘤内科,福州350001

出　　处：《创伤与急诊电子杂志》2014年第4期34-37,共4页Journal of Trauma and Emergency(Electronic Version)

摘　　要：目的：观察比较不同年龄阶段的患者对伊立替康（CPT-11）180mg/m2剂量下主要不良反应，尤其关注其消化道不良反应情况。方法回顾性选择本院住院的60例晚期结直肠癌（mCRC）患者，均接受FOLFIRI双周方案化疗6个疗程（其中CPT-11180mg/m2）后按照CTC-AE 4.0版评价标准进行不良反应的评估与比较。结果60例患者均出现了不同程度的细胞毒性不良反应，主要为骨髓抑制、恶心呕吐、腹泻、便秘，而肝肾功能均无明显损害，且在消化道不良反应情况方面，不同年龄段患者腹泻、便秘发生率不同并具有统计学差异。结论在排除UGT1A1基因7/7纯和突变的亚型情况下，经FOLFIRI双周方案6个周期（其中CPT-11为180 mg/m2）晚期姑息化疗，＜60岁与60～69岁患者发生腹泻的概率无统计学意义，而≥70岁的高龄患者更易发生便秘情况。Objective To observe and compare the major adverse reactions especially the gastrointestinal adverse reaction in patients of different age stages treated with therapy including CPT-11(180mg/m2).Method We chose 60 cases of patients with metastatic colonrectal cancer(m CRC) in our hospital, all of whom had taken 6 cycles of double week FOLFIRI chemotherapy(including CPT-11:180mg/m2).We evaluated and compared the adverse reactions according to the evaluation standard of CTC- AE version 4.0 afterwards. Result All of the 60 patients appeared different degrees of cytotoxic reactions, mainly in bone marrow suppression, nausea, vomiting, diarrhea and constipation, but without obvious damage to the liver or the kidney. Furthermore, patients in different age stages appeared statistical differences in the diarrhea and constipation adverse reaction.Conclusion Excluding the cases of UGT1A1 7/7 gene mutation,the incidence of diarrhoea in patients at 60 ~ 70 years of age and under 60 years of age are not statistically significant and those who are beyond 70 years old are more likely to develop constipation after 6 cycles of double-week FOLFIRI chemotherapy(including CPT-11:180mg/m2)

关 键 词：伊立替康 不良反应 便秘 晚期结直肠癌 

分 类 号：R735.3[医药卫生—肿瘤]